Update on the Diversification of Kratom-Derived Products: 7-Hydroxymitragynine, Pseudoindoxyl and Beyond

This session will provide a background on traditional kratom and an overview of the recent proliferation of novel, kratom-derived products. Industry marketing and media coverage will be described as all influence public health responses. Next steps for developing a better epidemiological understanding will be identified along with the roles clinicians play. The pharmacology of kratom, 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl will be explained in a manner geared at helping clinicians understand how pharmacology influences addiction potential. Patient-level factors that may influence substance use disorder or adverse event trajectories will be articulated. Use motivations will be discussed alongside risks.